The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Open accessAbstract
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events. Methods: We randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points. Results: Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% CI, 0.67–0.87]; P <0.0001). This benefit reached statistical significance at 18 days after randomization. Empagliflozin reduced the total number of heart failure hospitalizations that required intensive care (hazard ratio, 0.71 [95% CI, 0.52–0.96]; P =0.028) and the total number of all hospitalizations that required a vasopressor or positive inotropic drug (hazard ratio, 0.73 [95% CI, 0.55–0.97]; P =0.033). Compared with patients in the placebo group, fewer patients in the empagliflozin group reported outpatient intensification of diuretics (482 versus 610; hazard ratio, 0.76 [95% CI, 0.67–0.86]; P <0.0001), and patients assigned to empagliflozin were 20% to 50% more likely to have a better New York Heart Association functional class, with significant effects at 12 weeks that were maintained for at least 2 years. The benefit on total heart failure hospitalizations was similar in patients with an ejection fraction of >40% to <50% and 50% to <60%, but was attenuated at higher ejection fractions. Conclusions: In patients with heart failure with preserved ejection fraction, empagliflozin produced a meaningful, early, and sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03057977.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040130 · Cited by 557
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051783 · Cited by 435
Self-citationMazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
Anker, S. D., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., Kimura, K., Zeller, C., George, J., Brueckmann, M., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1596 · Cited by 250
Self-citationSha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Mode of Death in Heart Failure With Preserved Ejection Fraction
Vaduganathan, M., Patel, R. B., Michel, A., Shah, S. J., Senni, M., Gheorghiade, M., & Butler, J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.078 · Cited by 249
Self-citationJuni, R. P., Kuster, D. W. D., Goebel, M., Helmes, M., Musters, R. J. P., van der Velden, J., Koolwijk, P., Paulus, W. J., & van Hinsbergh, V. W. M. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.003 · Cited by 202
Berg, D. D., Jhund, P. S., Docherty, K. F., Murphy, S. A., Verma, S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.7585 · Cited by 189
Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020729 · Cited by 186
Self-citationPacker, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Self-citationJackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047077 · Cited by 175
Self-citationObesity-Related Heart Failure With a Preserved Ejection Fraction
Packer, M., & Kitzman, D. W. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.01.009 · Cited by 172
Self-citationLund, L. H., Donal, E., Oger, E., Hage, C., Persson, H., Löfman, I. H., Ennezat, P., Sportouch, C., Drouet, É., Daubert, J., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.137 · Cited by 141
Cappetta, D., Angelis, A. D., Ciuffreda, L. P., Coppini, R., Cozzolino, A., Miccichè, A., Dell’Aversana, C., D’Amario, D., Cianflone, E., Scavone, C., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104781 · Cited by 136
Borges, F. A., dos Santos, D. S., Benetti, A., Polidoro, J. Z., Wisnivesky, A. C. T., Crajoinas, R. O., Antônio, E. L., Jensen, L., Caramelli, B., Malnic, G., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020071029 · Cited by 99
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047480 · Cited by 95
Self-citationPacker, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.015 · Cited by 95
Self-citationMetabolomic Profile in HFpEF vs HFrEF Patients
Hage, C., Löfgren, L., Michopoulos, F., nilsson, R., Davidsson, P., Kumar, C., Ekström, M., Eriksson, M. J., Lyngå, P., Persson, B., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.07.010 · Cited by 87
Ohara, K., Masuda, T., Murakami, T., Imai, T., Yoshizawa, H., Nakagawa, S., Okada, M., Miki, A., Myoga, A., Sugase, T., et al. (2019) · Nephrology · doi:10.1111/nep.13552 · Cited by 81
Skali, H., Dwyer, E. M., Goldstein, R., Haigney, M., Krone, R., Kukin, M., Lichstein, E., McNitt, S., Moss, A. J., Pfeffer, M. A., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.71 · Cited by 76
Yasui, A., Lee, G., Hirase, T., Kaneko, T., Kaspers, S., von Eynatten, M., & Okamura, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0385-5 · Cited by 75
Cleland, J. G. F., Charlesworth, A., Lubsen, J. C., Swedberg, K. B., Remme, W. J., Erhardt, L., Lenarda, A. D., Michel Komajda, N., Metra, M., Torp-Pedersen, C. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.069 · Cited by 68
Rogers, J. K., Yaroshinsky, A., Pocock, S., Stokar, D., & Pogoda, J. M. (2016) · Statistics in Medicine · doi:10.1002/sim.6853 · Cited by 65
Self-citationCleland, J. G. F. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00039-9 · Cited by 47
Goyal, P., Loop, M. S., Chen, L., Brown, T. M., Durant, R. W., Safford, M. M., & Levitan, E. B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007785 · Cited by 43
Vaduganathan, M., Cunningham, J. W., Claggett, B. L., Causland, F. M., Barkoudah, E., Finn, P. V., Zannad, F. M., Pfeffer, M. A., Rizkala, A. R., Sabarwal, S. V., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.01.014 · Cited by 43
Self-citationPacker, M., Zannad, F. M., & Anker, S. D. (2021) · Circulation · doi:10.1161/circulationaha.121.056657 · Cited by 40
Self-citationKapłon‐Cieślicka, A., Laroche, C., Crespo-Leiro, M. G., Coats, A. J. S., Anker, S. D., Filippatos, G. S., Maggioni, A. P., Hage, C., Lara‐Padrón, A., Fucili, A., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12817 · Cited by 35
Self-citationDesai, R. J., Mahesri, M., Chin, K., Levin, R., Lahoz, R., Studer, R. L., Vaduganathan, M., & Patorno, E. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.09.038 · Cited by 33
Carson, P., Fiuzat, M., O'Connor, C., Anand, I., Plehn, J., Lindenfeld, J. A., Silver, M., White, M., Miller, A., Davis, G., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.004 · Cited by 31
Self-citationTyl, B., Lopez Sendon, J., Borer, J. S., Lopez De Sa, E., Lerebours, G., Varin, C., De Montigny, A., Pannaux, M., & Komajda, M. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006720 · Cited by 29
The Importance of Worsening Heart Failure in Ambulatory Patients
Mallick, A., Gandhi, P. U., Gaggin, H. K., Ibrahim, N., & Januzzi, J. L. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2016.03.012 · Cited by 25
Cited by
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Mebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02076-1 · Cited by 1,123
Self-citationVaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01429-5 · Cited by 996
Metadata
- Authors
- Packer, M., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., Komajda, M., Miller, A., Pehrson, S., Teerlink, J. R., Schnaidt, S., Zeller, C., Schnee, J. M., Anker, S. D., & for the EMPEROR-Preserved Trial Study Group
- Venue
- Circulation
- Published
- 2021-10-19
- Volume
- 144
- Issue
- 16
- Pages
- 1284-1294
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3198485697
- Cited by
- 354
- References
- 42
- FWCI
- 42.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.